It says right in the S-1 that getting the drug to the point of a trial will cost over a million dollars (earlier versions had $2M). The NIH is paying the bulk of the first clinical trial, but they have to get the drug to that point.
Student, what were the final results on the animal test? Was the results better than expected? In your opinion, have you talked to any big money about investing after the uplist?
News 
Market Data 
Discover 
